Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 4.56 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid; indigo carmine aluminium lake; iron oxide yellow - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 3.42 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid; indigo carmine aluminium lake; iron oxide yellow - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 2.28 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 1.14 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants).intuniv must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupropion hydrochloride, quantity: 150 mg - tablet, modified release - excipient ingredients: magnesium stearate; carnauba wax; cysteine hydrochloride; microcrystalline cellulose; hypromellose; titanium dioxide; macrogol 400; propylene glycol; purified water; isopropyl alcohol; iron oxide black - zyban sr tablets are indicated as a short-term adjunctive therapy for the treatment of nicotine dependence in those who are committed to quitting smoking, when used in conjunction with counselling for smoking cessation/abstinence.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - bisacodyl (unii: 10x0709y6i) (deacetylbisacodyl - unii:r09078e41y) - stimulant laxative - for relief of occasional constipation and irregularity - this product generally produces bowel movement in 6 to 12 hours

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - clonazepam, quantity: 0.5 mg - tablet, uncoated - excipient ingredients: iron oxide red; magnesium stearate; pregelatinised potato starch; purified talc; maize starch; iron oxide yellow; lactose monohydrate - tablets: most types epilepsy in infants and children, especially absences (petit mal), myoclonic seizures and tonic-clonic fits, whether due to primary generalised epilepsy, or to secondary generalisation of partial epilepsy. in adults all varieties of generalised epilepsy (including myoclonic, akinetic, tonic and tonic-clonic seizures), and in partial epilepsy (including psychomotor seizures).

Singapore - English - HSA (Health Sciences Authority)

ferring pharmaceuticals private limited - (tablet core) budesonide micronized - tablet, film coated, extended release - (tablet core) budesonide micronized 9.0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - dexamfetamine sulfate, quantity: 5 mg - tablet, uncoated - excipient ingredients: povidone; wheat starch; magnesium stearate; lactose monohydrate - indications as at 22 january 1997: narcolepsy and hyperkinetic behaviour disorders in children.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; maize starch; colloidal anhydrous silica; povidone - women: moderately severe to severe signs of androgenization. moderately severe/severe forms of hirsutism.moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe androgenic alopecia). moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenization.cyproterone acetate inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused either by increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment.if androcur is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of childbearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular menstruation.men:reduction of drive in sexual deviations androcur reduces the force of the sexual urge in men with sexual deviations. whilst under treatment the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a pre-requisite for therapy is the desire by the patient for treatment.androcur therapy should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social re-orientation.inoperable prostatic carcinoma to suppress "flare" with initial lhrh analogue therapy in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.